Eric Sherbet - IQVIA Holdings President
| IQV Stock | USD 184.26 0.00 0.00% |
President
Mr. Eric M. Sherbet is Executive Vice President, General Counsel, Secretary of the Company. He is responsible for the companys global legal operations, as well as compliance, privacy and external affairs. Eric has more than 25 years of legal experience, of which 17 are in the global life science and technology industries. Prior to joining IQVIA in February 2018, he served as general counsel and secretary at Patheon, where he oversaw the companys initial public offering and its recent 7.2 billion acquisition by Thermo Fisher. Before that, Eric was general counsel and secretary at InVentiv Health, where he built the legal and compliance division into a global team. He also served as vice president, deputy general counsel and corporate secretary at Foster Wheeler AG and as vice president, corporate and securities law and corporate secretary at Avaya. Eric earned his J.D. from the New York University School of Law and received his bachelors degree in commerceaccounting from the University of Virginia. Eric started his career as a CPA at KPMG. since 2018.
| Age | 60 |
| Tenure | 7 years |
| Professional Marks | CPA |
| Address | 2400 Ellis Road, Durham, NC, United States, 27703 |
| Phone | 919 998 2000 |
| Web | https://www.iqvia.com |
Latest Insider Transactions
Eric Sherbet Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Sherbet against IQVIA Holdings stock is an integral part of due diligence when investing in IQVIA Holdings. Eric Sherbet insider activity provides valuable insight into whether IQVIA Holdings is net buyers or sellers over its current business cycle. Note, IQVIA Holdings insiders must abide by specific rules, including filing SEC forms every time they buy or sell IQVIA Holdings'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Sherbet over six months ago Disposition of 1300 shares by Eric Sherbet of IQVIA Holdings at 246.33 subject to Rule 16b-3 |
IQVIA Holdings Management Efficiency
The company has Return on Asset of 0.0532 % which means that on every $100 spent on assets, it made $0.0532 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2255 %, implying that it generated $0.2255 on every 100 dollars invested. IQVIA Holdings' management efficiency ratios could be used to measure how well IQVIA Holdings manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IQVIA Holdings' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to climb to 0.06 in 2025, whereas Return On Tangible Assets are likely to drop 0.1 in 2025. At this time, IQVIA Holdings' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 375.9 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 14.3 B in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| William Barbo | Charles River Laboratories | 64 | |
| Ian King | Waters | 63 | |
| Brian Caveney | Laboratory of | 47 | |
| Ute Berger | ICON PLC | N/A | |
| Susan Burwig | Medpace Holdings | 61 | |
| Michael Harrington | Waters | 59 | |
| John Lynch | Waters | N/A | |
| David Smith | Charles River Laboratories | 58 | |
| JD MD | Laboratory of | 50 | |
| Thomas Schweins | Qiagen NV | N/A | |
| Simon Holmes | ICON PLC | 58 | |
| Glenn Eisenberg | Laboratory of | 64 | |
| Amol Chaubal | Waters | 48 | |
| James Miskel | ICON PLC | N/A | |
| Lance Berberian | Laboratory of | 61 | |
| Sharon Underberg | IDEXX Laboratories | 63 | |
| Sandra Vaart | Laboratory of | 64 | |
| Jonathan Sheldon | Qiagen NV | 53 | |
| Sherry Buck | Waters | 55 | |
| Birgit Girshick | Charles River Laboratories | 55 | |
| Patrick Finn | Twist Bioscience Corp | 53 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0532 |
IQVIA Holdings Leadership Team
Elected by the shareholders, the IQVIA Holdings' board of directors comprises two types of representatives: IQVIA Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IQVIA. The board's role is to monitor IQVIA Holdings' management team and ensure that shareholders' interests are well served. IQVIA Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IQVIA Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ari Bousbib, Chairman of the Board, President, Chief Executive Officer | ||
| Nicholas Childs, Senior Treasury | ||
| John Danhakl, Independent Director | ||
| Trudy Stein, Chief VP | ||
| Andrea Spannheimer, Global Research | ||
| Richard III, President Solutions | ||
| Walter Staub, President - Research and Development Solutions | ||
| Michael McDonnell, Chief Financial Officer, Executive Vice President | ||
| Andrew Markwick, VP Relations | ||
| Carol Burt, Independent Director | ||
| Jon Resnick, President Canada | ||
| John Leonard, Lead Independent Director | ||
| BBS ACMA, Chief Laboratories | ||
| Keriann Cherofsky, Corporate VP | ||
| Gregg Dearhammer, Safety Sciences | ||
| Cynthia Verst, President Innovation | ||
| Jeffrey MD, Global VP | ||
| James Fasano, Independent Director | ||
| Ronald Bruehlman, Interim Chief Financial Officer, Executive Vice President | ||
| Jeffrey Spaeder, Global VP | ||
| Eric JD, General VP | ||
| John Connaughton, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Nilton Paletta, President America | ||
| Todd Sisitsky, Independent Director | ||
| Bhavik Patel, President IQVIA | ||
| Eric Sherbet, Executive Vice President General Counsel, Secretary | ||
| Costa Panagos, President - Research & Development Solutions | ||
| Lucas Glass, Global Excellence | ||
| Rob Kotchie, President Solutions | ||
| Wendy Stewart, President Operations | ||
| Kerri Joseph, SVP Treasury | ||
| Jim Berkshire, Executive Operations | ||
| Alistair Grenfell, Middle Europe | ||
| Karl Guenault, Senior Officer | ||
| Ronald Rittenmeyer, Independent Director | ||
| Brian Mi, President Pacific | ||
| Kevin Knightly, President - Information and Technology Solutions |
IQVIA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IQVIA Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0532 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 45.56 B | ||||
| Shares Outstanding | 176.32 M | ||||
| Shares Owned By Insiders | 0.88 % | ||||
| Shares Owned By Institutions | 95.86 % | ||||
| Number Of Shares Shorted | 3.51 M | ||||
| Price To Earning | 103.68 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IQVIA Stock Analysis
When running IQVIA Holdings' price analysis, check to measure IQVIA Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IQVIA Holdings is operating at the current time. Most of IQVIA Holdings' value examination focuses on studying past and present price action to predict the probability of IQVIA Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IQVIA Holdings' price. Additionally, you may evaluate how the addition of IQVIA Holdings to your portfolios can decrease your overall portfolio volatility.